Mark Feng

Mark Feng has over 20 years of experience in the pharmaceutical industry. Mark began their career in 2000 at Apotex Inc., Canada, as a Scientific Leader in Analytical R&D. In 2005, they moved to Watson Pharmaceuticals Inc. as a Senior Principal Scientist in Analytical R&D. In 2011, they joined Teva Pharmaceuticals, USA, as an Associate Director in Analytical R&D. In 2018, they became Senior Director in Analytical R&D at Edenbridge Pharmaceuticals, LLC. In 2020, they were appointed Director of Analytical Development and Quality Control at Assembly Biosciences, Inc. Most recently, in 2022, they were appointed Director of Analytical Development at Ashvattha Therapeutics, Inc.

Mark Feng holds a Ph.D. in Organic/Polymer Chemistry from the University of Twente, and a B. Sci. in Polymer Chemistry from Wuhan University.